Keppra, the brand name for levetiracetam, is a widely prescribed antiepileptic drug (AED) used to manage various types of seizures in both children and adults. Since its approval by the U.S. Food and Drug Administration (FDA) in 1999, Keppra has become a cornerstone in epilepsy treatment due to its favorable pharmacokinetic profile, broad-spectrum efficacy, and relatively favorable side-effect profile compared to older AEDs. This report provides a concise yet detailed overview of Keppra, covering its mechanism of action, clinical uses, dosing, adverse effects, drug interactions, and special considerations.
Mechanism of Action
Unlike many traditional AEDs that act primarily on sodium or calcium channels or enhance GABAergic inhibition, levetiracetam has a unique mechanism. It binds selectively to the synaptic vesicle protein 2A (SV2A) in neurons. SV2A is involved in vesicle exocytosis and neurotransmitter release; by modulating its function, levetiracetam reduces excessive neuronal firing and seizure propagation without directly affecting normal neuronal transmission. This distinct mechanism contributes to its broad-spectrum activity against both focal and generalized seizures. Additional effects have been observed on calcium channels and GABAergic systems, but the SV2A binding is considered the primary driver of its anticonvulsant action.
Clinical Indications
Keppra is approved as monotherapy and adjunctive therapy for:
- Partial-onset (focal) seizures in adults and children aged 1 month and older.
- Myoclonic seizures in patients aged 12 years and older with juvenile myoclonic epilepsy.
- Primary generalized tonic-clonic seizures in patients aged 6 years and older with idiopathic generalized epilepsy.
Pharmacokinetics
Levetiracetam exhibits near-complete oral bioavailability (>95%), with peak plasma concentrations reached within 1 hour. It is not extensively bound to plasma proteins (<10%) and has minimal hepatic metabolism—only about 24% is hydrolyzed by enzymatic esterases in blood and tissues to an inactive metabolite. The majority (66%) is excreted unchanged in the urine via glomerular filtration and tubular reabsorption. The elimination half-life is approximately 6–8 hours in adults but may be prolonged in the elderly or those with renal impairment. Dose adjustment is required based on creatinine clearance.
Dosing and Administration
Keppra is available in oral tablets (250, 500, 750, 1000 mg), oral solution (100 mg/mL), and intravenous solution (100 mg/mL). For adults with focal seizures, the typical starting dose is 500 mg twice daily, titrated upward by 500 mg every two weeks up to a target of 1500–3000 mg/day (split into two doses). Higher doses (up to 4000 mg/day) may be used in some patients. For children, weight-based dosing is used. Intravenous Keppra is used when oral administration is not feasible, given as an infusion over 15 minutes.
Adverse Effects
Keppra is generally well-tolerated, but common side effects include somnolence, dizziness, asthenia, and coordination difficulties. Behavioral and psychiatric changes are notable—irritability, aggression, anxiety, and mood swings occur in a minority of patients, especially in children and those with pre-existing psychiatric conditions. Rare but serious side effects include severe allergic reactions (Stevens-Johnson syndrome), blood dyscrasias (pancytopenia, (https://francescobarletta.it/images/products/atarax.webp) leukopenia), and acute kidney injury. Suicidal ideation and behavior have been reported, as with all AEDs, requiring monitoring. Cognitive effects are less pronounced than with many other AEDs, but some patients experience mild memory or attention issues.
Drug Interactions
One of the major advantages of Keppra is its minimal drug-drug interaction potential. It does not induce or inhibit hepatic cytochrome P450 enzymes or glucuronidation. Therefore, it does not affect the metabolism of other AEDs, oral contraceptives, warfarin, or other medications. However, certain drugs that affect renal function (e.g., NSAIDs, probenecid) may theoretically reduce levetiracetam clearance via competition for tubular secretion, but clinically significant interactions are rare. Concomitant use with other CNS depressants (e.g., benzodiazepines, alcohol) may enhance sedation.
Special Populations
- Pediatric: Keppra is approved from age 1 month upward. Dosing is weight-based, and behavioral side effects are more common.
- Elderly: Age-related renal decline may necessitate lower doses; monitoring for sedation and cognitive effects is recommended.
- Pregnancy and Lactation: Levetiracetam is classified as pregnancy category C (increased risk of major congenital malformations, especially at higher doses). Many experts consider it a preferred AED during pregnancy due to lower teratogenic risk than valproate, but folic acid supplementation is essential. It is excreted in breast milk, but benefits usually outweigh risks.
- Renal Impairment: Dose adjustment is critical—dosing intervals or total daily doses must be reduced based on creatinine clearance (e.g., 500 mg every 12 hours for mild impairment, up to 500 mg every 24 hours for severe). Hemodialysis removes levetiracetam, so a supplemental dose is given after dialysis.
Large randomized controlled trials have demonstrated that Keppra is effective for both initial monotherapy and adjunctive therapy for partial seizures, with responder rates (≥50% seizure reduction) significantly higher than placebo. In myoclonic and generalized tonic-clonic seizures, modest but meaningful reductions have been shown. Its rapid oral absorption and linear pharmacokinetics allow predictable dosing. Intravenous formulation provides rapid loading in acute settings.
Comparison with Other AEDs
Keppra is often favored over older AEDs because it has no significant drug interactions, does not require serum level monitoring, and has a relatively forgiving safety profile. However, its potential for behavioral side effects may prompt clinicians to choose alternatives like lamotrigine or lacosamide in patients with psychiatric comorbidities. The drug's short half-life also means that missed doses can lead to breakthrough seizures more quickly than with some longer-acting AEDs.
Conclusion
Keppra (levetiracetam) is a valuable, well-studied antiepileptic agent with a unique mechanism through SV2A binding. Its broad-spectrum efficacy, excellent absorption, minimal drug interactions, and good tolerability make it a first-line option for many seizure types across all ages. Clinicians must monitor for psychiatric side effects and adjust dosing in renal impairment. Overall, Keppra has significantly improved the management of epilepsy since its introduction and remains an essential medication in modern neurology.